LYT-200

DRUG2 trials

Sponsors

PureTech

Conditions

AML, Adult RecurrentColorectal CancerHead and Neck CancerMDSMetastatic CancerPancreatic CancerSolid TumorUrothelial Carcinoma

Phase 1

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

CompletedNCT04666688

PureTechColorectal Cancer, Head and Neck Cancer, Metastatic Cancer +3

Start: 2020-12-15End: 2024-12-12Updated: 2025-02-12

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

RecruitingNCT05829226

PureTechAML, Adult Recurrent, MDS

Start: 2022-12-12End: 2026-03-31Target: 90Updated: 2025-05-28

Related Papers

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Blood2024-11-053 citations

128P A phase I dose escalation and expansion trial of LYT-200: A galectin-9 antibody +/- tislelizumab

Immuno-Oncology Technology2023-12-012 citations

Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies

Blood2022-11-156 citations

482 Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

Regular and Young Investigator Award Abstracts2021-11-0110 citations